Search Results - "Jobanputra, Kunal"

First year of residency: As the dust settles by Jobanputra, Kunal

Get full text

Demographic insights into head-and-neck cancers by Jobanputra, Kunal

Get full text

Phase III randomized controlled trial of gefitinib versus chemotherapy in EGFR-positive treatment-naïve metastatic lung cancer: Long-term outcome after eight years by Singh, Ajaykumar, Patil, Vijay, Menon, Nandini, More, Sucheta, Jain, Srushti, Goud, Supriya, Shah, Darshit, Shah, Minit, Jobanputra, Kunal, Ubharay, Ahmad

“…Background: This was the first Phase III randomized study comparing an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib, to…”
Get full text

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India by Tiwari, Atul, Singh, Ajay Kumar, Noronha, Vanita, Patil, Vijay M., Menon, Nandini, Shah, Minit J., Shah, Darshit, Jobanputra, Kunal, Trikha, Mehak, Ubharay, Ahmad, Yadav, Shashikant, Majumdar, Anuradha, Chandrani, Pratik, Kumar, Rajiv K., Pai, Trupti, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar

“…Osimertinib is approved in the first line in patients with mutations in the sensitive gene epidermal growth factor receptor (EGFR) mutation. There is lack of…”
Get full text

Authors' reply to Jayakar and Bagal et al by Jain, Hasmukh, Jobanputra, Kunal, Thorat, Jayashree

Get full text

Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC) by Kashyap, Lakhan, Patil, Vijay, Noronha, Vanita, Joshi, Amit, Menon, Nandini, Jobanputra, Kunal, Saha, Saswata, Chaturvedi, Pankaj, Banavali, Shripad D, Prabhash, Kumar

“…A combination of maximum tolerated dose and metronomic chemotherapy schedule may lead to synergistic effects with acceptable toxicity. We assessed the efficacy…”
Get full text

Diffuse Large B-Cell Lymphoma in the Elderly : Retrospective Analysis from a Single Tertiary Cancer Center in India by Jobanputra, Kunal N., Nayak, Lingaraj, Jain, Hasmukh, Sengar, Dr. Manju

“…Introduction Diffuse large B-cell lymphoma (DLBCL) commonly affects the elderly population and the treatment is often challenging because of the close…”
Get full text

Impact of pre-treatment anemia on survival in locally advanced head neck squamous cell carcinomas treated with radiation with or without concurrent chemotherapy by Shah, Minit Jalan, Patil, Vijay Maruti, Noronha, Vanita, Menon, Nandini Sharrel, Singh, Ajaykumar Chandrabhan, Jobanputra, Kunal Naishadh, Peelay, Zoya Ravish, Prabhash, Kumar

“…e18079 Background: Locally advanced head neck squamous cell carcinomas (LAHNSCCs) are treated either with surgery followed by radiation (RT) alone, surgery…”
Get full text

Exploring the significance of MET overexpression by gene expression profiling versus immunohistochemistry in an EGFR-mutant lung cancer cohort by Vaid, Ashok K, Vijayakumar, Rajeev, Kulkarni, Shriniwas Subhash, Ajami, Ramin, Choudhary, R K, Koppaka, Deepak, Reddy, Vijay Anand, Rishikesh, Kumar, Bose, Chirantan, Maheshwari, Dr Udip, Jobanputra, Kunal Naishadh, Vijayan, Poornima, Apurwa, Sachin, Akolkar, Dadasaheb, Datta, Vineet, Patil, Darshana, Limaye, Sewanti

“…e20600 Background: Amivantamab, an innovative EGFR-MET bispecific antibody, approved for use in EGFR exon 20 mutated lung cancers, recently demonstrated…”
Get full text

Infections in Systemic Lupus Erythematosus by Rajadhyaksha, Anjali G, Jobanputra, Kunal

“…Infections are a major cause of morbidity and mortality in patients of Systemic Lupus erythematosus (SLE). We therefore aimed to determine the spectrum of…”
Get full text

Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation by Patil, Vijay Maruti, Noronha, Vanita, Menon, Nandini, Singh, Ajay, Ghosh-Laskar, Sarbani, Budrukkar, Ashwini, Bhattacharjee, Atanu, Swain, Monali, Mathrudev, Vijayalakshmi, Nawale, Kavita, Balaji, Arun, Peelay, Zoya, Alone, Mitali, Pathak, Shruti, Mahajan, Abhishek, Kumar, Suman, Purandare, Nilendu, Agarwal, Archi, Puranik, Ameya, Pendse, Shantanu, Reddy Yallala, Monica, Sahu, Harsh, Kapu, Venkatesh, Dey, Sayak, Choudhary, Jatin, Krishna, Madala Ravi, Shetty, Alok, Karuvandan, Naveen, Ravind, Rahul, Rai, Rahul, Jobanputra, Kunal, Chaturvedi, Pankaj, Pai, Prathamesh S, Chaukar, Devendra, Nair, Sudhir, Thiagarajan, Shivakumar, Prabhash, Kumar

“…There is a lack of published literature on systemic therapeutic options in cisplatin-ineligible patients with locally advanced head and neck squamous cell…”
Get full text

Poster: ABCL-322 Retrospective Analysis of Real-World Outcomes in Older Adult Patients With Diffuse Large B-Cell Lymphoma by Jobanputra, Kunal, Nayak, Lingaraj, Jain, Hasmukh, Bonda, V.N.Avinash, Thorat, Jayashree, Bagal, Bhausaheb, Sengar, Manju

Get full text

ABCL-322 Retrospective Analysis of Real-World Outcomes in Older Adult Patients With Diffuse Large B-Cell Lymphoma by Jobanputra, Kunal, Nayak, Lingaraj, Jain, Hasmukh, Bonda, V.N.Avinash, Thorat, Jayashree, Bagal, Bhausaheb, Sengar, Manju

Get full text

A comparative study evaluating the quality of life in patients receiving chemotherapy versus oral TKI in the third line and beyond setting for advanced non–small-cell lung cancer by Menon, Nandini Sharrel, Noronha, Vanita, Patil, Vijay Maruti, Singh, Ajaykumar Chandrabhan, Purandare, Nilendu, Mahajan, Abhishek, Janu, Amit, More, Sucheta, Goud, Supriya, Shah, Srushti, Jobanputra, Kunal Naishadh, Karuvandan, Naveen, Sarma, Rup Jyoti, Patel, Dhwani, Joarder, Ritam, SHAH, DARSHIT KALPESHKUMAR, Shah, Minit Jalan, John, Anupa, Kumar, Prashant, Prabhash, Kumar

“…e21195 Background: The outcomes in advanced non-small cell lung cancer (NSCLC) have improved due to the availability of more effective systemic & improved…”
Get full text

Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I/II randomized study by Noronha, Vanita, Patil, Vijay, Menon, Nandini, Kalra, Devanshi, Singh, Ajaykumar, Shah, Minit, Goud, Supriya, Jobanputra, Kunal, Nawale, Kavita, Shah, Srushti, Chowdhury, Oindrila Roy, Mathrudev, Vijayalakshmi, Jogdhankar, Shweta, Singh, Madhu Yadav, Singh, Ashish, Adak, Supriya, Sandesh, Mayuri, Arunkumar, R., Kumar, Suman, Mahajan, Abhishek, Prabhash, Kumar

“…Pantoprazole decreases the acidity of the tumor microenvironment by inhibiting proton pumps on the cancer cell. This possibly leads to increased sensitivity to…”
Get full text

Diffuse Large B-Cell Lymphoma in the Elderly: Real-World Outcomes From a Developing Country by Jobanputra, Kunal, Nayak, Lingaraj, Jain, Hasmukh, Shet, Tanuja, Epari, Sridhar, Bonda, V.N. Avinash, Thorat, Jayashree, Bagal, Bhausaheb, Laskar, Siddhartha, Rangarajan, Venkatesh, Agrawal, Archi, Gujral, Sumeet, Khanna, Nehal, Goda, Jayant Sastri, Sengar, Manju

“…Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) in the elderly aims to achieve disease remission while minimizing treatment-related toxicities. The use of…”
Get full text

COVID‐19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment by Ramaswamy, Anant, Nayak, Lingaraj, Roy Moulik, Nirmalya, Sengar, Manju, Chinnaswamy, Girish, Jobanputra, Kunal, Shah, Minit J., Kapoor, Akhil, Joshi, Amit, Kumar, Amit, Gokarn, Anant, Bonda, Avinash, Cheriyalinkal Parambil, Badira, Prasad, Maya, Bagal, Bhausaheb, Dhamne, Chetan, Narula, Gaurav, Jain, Hasmukh, Ghosh, Jaya, Thorat, Jayashree, Bajpai, Jyoti, Menon, Nandini, Khattry, Navin, Bhargava, Prabhat, Punatar, Sachin, Gulia, Seema, Banavali, Shripad, Gupta, Sudeep, Srinivas, Sujay, Rath, Sushmita, Vora, Tushar, Noronha, Vanita, Patil, Vijay M., Ostwal, Vikas, Prabhash, Kumar

“…Background There is limited data on outcomes in cancer patients with coronavirus disease 2019 (COVID‐19) from lower middle‐income countries (LMICs). Patients…”
Get full text

A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLC by Noronha, Vanita, Menon, Nandini S., Patil, Vijay Maruti, Chandrakanth, M.V., More, Sucheta, Dhanawat, Aditya, Chowdhary, Oindrila Roy, Singh, Ajaykumar Chandrabhan, Goud, Supriya, Shah, Srushti, Karuvandan, Naveen, Jobanputra, Kunal Naishadh, Shah, Darshit Kalpeshkumar, Shah, Minit Jalan, Sarma, Rupjyoti, Patel, Dhwaniben, Joarder, Ritam, Kumar, Prashant, John, Anupa, Kaur, Jaspreet, Bagra, Saurabh, Purandare, Nilendu, Janu, Amit, Mahajan, Abhishek, Prabhash, Kumar

“…The outcomes in advanced NSCLC have improved owing to the availability of more effective systemic and improved supportive care. This has increased the number…”
Get full text